Orphazyme will be scrutinizing its expenses after the US Food and Drug Authority, the FDA, rejected its main candidate arimoclomol for the treatment of the metabolic disease Niemann-Pick type C, also known as NPC.
According to Orphazyme's CEO Christophe Bourdon, the company has started looking into what will happen to the US organization, in which it has invested large sums in recent months in order to prepare for the potential launch. The rejection from the FDA, announced on Friday, has turned this into more of a long-term prospect.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
Rumored purchase of GN Group could mean divestment of hearing aid division, says media
Inside Business has learned that a number of buyers might be looking to buy GN Store Nord stock while it’s cheap, with the plan to sell one division, GN Hearing, while keeping Audio.
EMA publishes new plan to support antibiotic development
Drug-resistant bacteria kill hundreds of thousands of people every year, and national regulatory forces across the world are now coming together to ensure a uniform approach to clinical trials for antibiotics.
Client Talent Acquisition Specialist 
Clinical Trial Administrator 
Chemist for Incoming Materials in QC Department 
Analytical Coordinator for Analytical Development 
Industrial Designer- Design Engineer 
2 Sales Representatives and Product Specialists 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Clinical Trial Manager 
Senior Chemical Safety Advisor 
Director for innovative pre-clinical testing unit 
Nordic Medical Affairs Manager 
Senior Manager, Clinical Trial Budget 
(Senior) Drug Substance Specialist 
System Sales Development Consultant - Investment Projects, Merck Millipore